Consistent with our previous reports on co‐occurrence of SPRY2 and PTEN alterations in prostate cancer (Gao et al, 2012; Patel et al, 2013), SPRY2 and PTEN levels significantly correlated in CRPC (Fig EV1C). The gene discussed is PTEN; the disease is prostate carcinoma.